Mr. Robert Farrell reports

KALYTERA ANNOUNCES REVOCATION OF FFCTO

Kalytera Therapeutics Inc.'s previously announced cease trade order has been revoked.

On June 22, 2020, the B.C. Securities Commission (the BCSC) and the Ontario Securities Commission (the OSC) issued a failure-to-file cease trade order against the company (the FFCTO) due to the company's failure to file by the prescribed filing deadlines its annual financial statements for the year ended Dec. 31, 2019, and the accompanying management's discussion and analysis and certifications. As a result, the TSX Venture Exchange also suspended trading of the company's common shares. The company's auditor, BDO, has now completed the audit of the company's financial statements for the year ended Dec. 31, 2019, and the company has now filed the audited financial statements for 2019, the quarterly financial statements for first quarter 2020 (for the period ended March 31, 2020), second quarter 2020 (for the period ended June 30, 2020) and third quarter 2020 (for the period ended Sept. 30, 2020), and the accompanying management's discussion and analysis and certifications for all three periods. The company applied to the BCSC and the OSC on Nov. 4, 2020, to have the FFCTO fully revoked, and applied to the TSX-V on Oct. 30, 2020, to have the company's shares resume trading after the FFCTO has been fully revoked. The BCSC and the OSC granted the full revocation with respect of the FFCTO on Jan. 22, 2021. The company is following up with the TSX-V to remove its suspension and resume the trading of the company's common shares, which resumption when effected will be confirmed in a follow-up press release.

The company confirms that its business has not changed, the company remains active and there are no changes to its current business plans.

About Kalytera Therapeutics Inc.

Kalytera is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for patients with significant unmet medical needs.

We seek Safe Harbor.